TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9468233

Group type: EXPERIMENTAL
Intervention: Amitriptyline 50 mg taken at bedtime
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 7892497

Group type: EXPERIMENTAL
Intervention: Proton magnetic resonance (MR) spectroscopy in patients with probable Alzheimer disease (AD)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Proton magnetic resonance (MR) spectroscopy in patients with other dementias (OD)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: MI/NAA ratio in patients with probable Alzheimer disease (AD)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: MI/creatine ratio in patients with other dementias (OD)
Number of subjects: 114
Study: 2642313

Group type: EXPERIMENTAL
Intervention: Otis internal urethrotomy
Number of subjects: 185

Group type: COMPARATOR
Intervention: 2-day urethral catheter dilation
Number of subjects: 185

Group type: COMPARATOR
Intervention: Polytetrafluoroethylene coated resectoscope sheath
Number of subjects: 185

Group type: COMPARATOR
Intervention: Uninsulated metal resectoscope sheath
Number of subjects: 185
Study: 7035030

Group type: EXPERIMENTAL
Intervention: 2 X 10(8) killed armadillo-derived M. leprae
Number of subjects: 0

Group type: COMPARATOR
Intervention: Live BCG and killed M. leprae (mixture)
Number of subjects: 0

Group type: COMPARATOR
Intervention: BCG
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Armadillo-derived M. leprae
Number of subjects: 0
Study: 31539605

Group type: EXPERIMENTAL
Intervention: PREPARE arm
Number of subjects: 986

Group type: COMPARATOR
Intervention: Advance directive-only arm
Number of subjects: 986

Group type: COMPARATOR
Intervention: Between-group comparisons
Number of subjects: 986
Study: 28634822

Group type: EXPERIMENTAL
Intervention: EPA (1800 mg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study: 26445565

Group type: EXPERIMENTAL
Intervention: Turkish coffee (3 mg·kg(‐1) BW of caffeine)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Decaffeinated Turkish coffee
Number of subjects: 20
Study: 23393144

Group type: EXPERIMENTAL
Intervention: Follow-up by a clinical nurse specialist (CNS)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Follow-up by a medical doctor (MD)
Number of subjects: 68
Study: 21710137

Group type: EXPERIMENTAL
Intervention: Instructional materials describing how to rate child ADHD symptoms
Number of subjects: 100

Group type: COMPARATOR
Intervention: No instructional materials
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Instructional materials
Number of subjects: 100
Study: 19427428

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 15603

Group type: COMPARATOR
Intervention: Placebo plus aspirin
Number of subjects: 15603

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 15603

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15603
Study: 19425467

Group type: EXPERIMENTAL
Intervention: Glyconutritional supplement
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control substance
Number of subjects: 62
Study: 15745291

Group type: EXPERIMENTAL
Intervention: Passive continuous infusion by gravitational force (Group 1)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Manually controlled pressure bag infusion at about 40 mmHg (Group 2)
Number of subjects: 147
Study: 12227872

Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide (Triaz 6% special gel), applied twice daily for 14 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Clindamycin (1% clindamycin phosphate in Cleocin-T lotion), applied twice daily for 14 days
Number of subjects: 20
Study: 9231932

Group type: EXPERIMENTAL
Intervention: Toremifene (TOR) 60 mg daily
Number of subjects: 415

Group type: COMPARATOR
Intervention: Tamoxifen (TAM) 40 mg daily
Number of subjects: 415
Study: 8381298

Group type: EXPERIMENTAL
Intervention: Cereal fibre intake
Number of subjects: 147

Group type: COMPARATOR
Intervention: Polyunsaturated fat intake
Number of subjects: 147

Group type: COMPARATOR
Intervention: Total fibre intake
Number of subjects: 147
Study: 3307390

Group type: EXPERIMENTAL
Intervention: Peripheral iv infusion of a 900 mosmol amino acid-glucose solution (2 L/day) for 21 days
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 28
Study: 11680575

Group type: EXPERIMENTAL
Intervention: 600 mg ribavirin/day (group A)
Number of subjects: 69

Group type: COMPARATOR
Intervention: 1,000-1,200 mg ribavirin/day (group B)
Number of subjects: 69
Study: 29150328

Group type: EXPERIMENTAL
Intervention: AAFP 500mg daily plus 4mg methylprednisolone BID
Number of subjects: 53

Group type: COMPARATOR
Intervention: OAA 1000mg daily plus 5mg prednisone BID
Number of subjects: 53
Study: 26458911

Group type: EXPERIMENTAL
Intervention: CogniPlus training (20 sessions, twice a week)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Physical training (30 min daily for 10 weeks)
Number of subjects: 80
Study: 25378467

Group type: EXPERIMENTAL
Intervention: Dronedarone with digoxin
Number of subjects: 1619

Group type: COMPARATOR
Intervention: Placebo with digoxin
Number of subjects: 1619

Group type: EXPERIMENTAL
Intervention: Dronedarone without digoxin
Number of subjects: 1619

Group type: COMPARATOR
Intervention: Placebo without digoxin
Number of subjects: 1619
Study: 19686283

Group type: EXPERIMENTAL
Intervention: CNC titanium frameworks
Number of subjects: 126

Group type: COMPARATOR
Intervention: Gold-alloy castings
Number of subjects: 126
Study: 19688282

Group type: EXPERIMENTAL
Intervention: Occupational therapy-led lifestyle intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine general practitioner's care
Number of subjects: 0
Study: 18791687

Group type: EXPERIMENTAL
Intervention: 2-Gy gamma radiation exposure
Number of subjects: 0
Study: 16034044

Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen treatment for 2 years
Number of subjects: 564
Study: 12119513

Group type: EXPERIMENTAL
Intervention: Distant healing
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control (no distant healing)
Number of subjects: 400
Study: 10514156

Group type: EXPERIMENTAL
Intervention: Expert system based on the transtheoretical model of behaviour change, incorporating three sessions using an expert system computer program and three class lessons.
Number of subjects: 8352

Group type: COMPARATOR
Intervention: Health education as part of the English national curriculum (Control group).
Number of subjects: 8352
Study: 8610286

Group type: EXPERIMENTAL
Intervention: Pericardial closure with PHB patch
Number of subjects: 50

Group type: COMPARATOR
Intervention: No pericardial patch (control group)
Number of subjects: 50
Study: 1782306

Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg b.d.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Famotidine 40 mg nocte
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Famotidine (20 mg) b.d.
Number of subjects: 0
Study: 6109989

Group type: EXPERIMENTAL
Intervention: Pancuronium bromide (muscle relaxation)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (no muscle relaxation)
Number of subjects: 50
Study: 31277176

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104
Study: 29216868

Group type: EXPERIMENTAL
Intervention: Structured personal diabetes care for 6 years
Number of subjects: 1381
Study: 26445178

Group type: EXPERIMENTAL
Intervention: Gum chewing (3 times a day for >5 minutes each time from postoperative day 1 to the first day of food intake)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 48
Study: 24306134

Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g/kg for males, 0.75 g/kg for females)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 30
Study: 21706245

Group type: EXPERIMENTAL
Intervention: Ketoprofen
Number of subjects: 316
Study: 19683086

Group type: EXPERIMENTAL
Intervention: Booster dose given 5 years post-primary vaccination (Group Y5)
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Booster dose given 10 years post-primary vaccination (Group Y10)
Number of subjects: 559
Study: 17464746

Group type: EXPERIMENTAL
Intervention: CAM assay
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Human clinical studies
Number of subjects: 24
Study: 28079517

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination (FDC) of candesartan and rosuvastatin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Co-administration of candesartan and rosuvastatin
Number of subjects: 40
Study: 12132492

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 0
Study: 10065905

Group type: EXPERIMENTAL
Intervention: Antipsychotic drugs (neuroleptics, major tranquillizers)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Benzodiazepines
Number of subjects: 0
Study: 7909402

Group type: EXPERIMENTAL
Intervention: Best 'drug' therapy (class I or class III antiarrhythmic therapy)
Number of subjects: 34

Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 34
Study: 3048121

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 31385858

Group type: EXPERIMENTAL
Intervention: Balloon dilation of the Eustachian tube
Number of subjects: 47
Study: 27856288

Group type: EXPERIMENTAL
Intervention: aCT1 gel formulation plus conventional standard of care protocols
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 0
Study: 25588457

Group type: EXPERIMENTAL
Intervention: Single hyaluronate injection (HI group)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Conservative management (CM group)
Number of subjects: 29
Study: 24037998

Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 15

Group type: COMPARATOR
Intervention: No bosentan (control)
Number of subjects: 15
Study: 22359979

Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg once a week or Ibandronate 50 mg once a month
Number of subjects: 341
Study: 19252043

Group type: EXPERIMENTAL
Intervention: Enhanced brief interpersonal psychotherapy (IPT-B)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Enhanced IPT-B
Number of subjects: 53
Study: 17127494

Group type: EXPERIMENTAL
Intervention: Four-dimensional (4D) ultrasound
Number of subjects: 63
Study: 15641878

Group type: EXPERIMENTAL
Intervention: Risperidone (plus placebo)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Paroxetine (plus placebo)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of risperidone and paroxetine
Number of subjects: 30
Study: 10944645

Group type: EXPERIMENTAL
Intervention: Individualized counseling aimed at limiting fat intake to 30% to 35% of daily energy, with a saturated:monounsaturated:polyunsaturated fatty acid ratio of 1:1:1 and cholesterol intake of less than 200 mg/d (n = 540)
Number of subjects: 496

Group type: COMPARATOR
Intervention: Usual health education (control group, n = 522)
Number of subjects: 496
Study: 8628561

Group type: EXPERIMENTAL
Intervention: 0.1% DfNa eye drops three times daily
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 17
Study: 1481685

Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids (BCAAs) supplementation (7.5-12 g) during exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6377249

Group type: EXPERIMENTAL
Intervention: Diflunisal
Number of subjects: 249

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 249
Study: 31047687

Group type: EXPERIMENTAL
Intervention: Intravenous tissue‐plasminogen activator (IV tPA)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (MT)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Combined treatment decisions (IV tPA and MT)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Diffusion‐Weighted‐Imaging‐Alberta‐Stroke‐Program‐EArly‐CT‐Score (DWI‐ASPECTS)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: RCT willingness
Number of subjects: 41
Study: 27529575

Group type: EXPERIMENTAL
Intervention: In-home telerehabilitation (TELE)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Usual face-to-face home visit (STD) rehabilitation
Number of subjects: 205
Study: 25808292

Group type: EXPERIMENTAL
Intervention: BDP/FF pMDI with VHC
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: BDP/FF pMDI without VHC
Number of subjects: 60

Group type: COMPARATOR
Intervention: Free combination of BDP pMDI and FF pMDI
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: BDP/FF pMDI in adolescents
Number of subjects: 60
Study: 23380000

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Performance Improvement Initiative
Number of subjects: 440
Study: 21725513

Group type: EXPERIMENTAL
Intervention: Dopamine with saline solution before endoscopic biliary drainage (n=64)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Saline solution alone before endoscopic biliary drainage (n=38)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Additional dopamine administration during the postdrainage phase (n=31)
Number of subjects: 102

Group type: COMPARATOR
Intervention: No additional dopamine administration during the postdrainage phase (n=33)
Number of subjects: 102
Study: 19520360

Group type: EXPERIMENTAL
Intervention: Guanfacine (1 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 18025315

Group type: EXPERIMENTAL
Intervention: Irrigation with large volume and low positive pressure (n = 64)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Spray (n = 63)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 127
Study: 15025747

Group type: EXPERIMENTAL
Intervention: Fluvoxamine 50 mg daily for 6 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 12423708

Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg/day) added to ongoing statin therapy
Number of subjects: 769

Group type: COMPARATOR
Intervention: Placebo added to ongoing statin therapy
Number of subjects: 769

Group type: EXPERIMENTAL
Intervention: Ezetimibe plus statin
Number of subjects: 769

Group type: COMPARATOR
Intervention: Placebo plus statin
Number of subjects: 769
Study: 10890228

Group type: EXPERIMENTAL
Intervention: Pentaglobin (5 ml/kg body weight intravenously each day for 5 days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (5% glucose solution with 1% human albumin, 5 ml/kg body weight intravenously each day for 5 days)
Number of subjects: 100
Study: 8688309

Group type: EXPERIMENTAL
Intervention: Enoxaparin (ENX), 75 anti-Xa IU/kg (n = 100)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH), 50 IU/kg (n = 101)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Enoxaparin (ENX), 75 anti-Xa IU/kg
Number of subjects: 201

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Enoxaparin (ENX)
Number of subjects: 201
Study: 1707570

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with nitrosomethylurea, vincristine, and peplomycin
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with nitrosomethylurea, vincristine, and bleomycetin
Number of subjects: 129

Group type: COMPARATOR
Intervention: Single-agent treatment with dacarbazine
Number of subjects: 129
Study: 7049819

Group type: EXPERIMENTAL
Intervention: Dilazep 300 mg/die
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nifedipine 30 mg/die
Number of subjects: 50
Study: 3971651

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside alone (group 1; n = 10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nitroprusside-trimethaphan mixture (group 2; n = 10)
Number of subjects: 20
Study: 29694464

Group type: EXPERIMENTAL
Intervention: Cervical and orofacial group (COG)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Cervical group (CG)
Number of subjects: 45
Study: 27760129

Group type: EXPERIMENTAL
Intervention: Insulin degludec/insulin aspart (IDegAsp) once daily (OD)
Number of subjects: 530

Group type: COMPARATOR
Intervention: Insulin glargine U100 (IGlar) once daily (OD)
Number of subjects: 530
Study: 24188161

Group type: EXPERIMENTAL
Intervention: Milnacipran (100 mg/day)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Milnacipran (200 mg/day)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 321
Study: 22500253

Group type: EXPERIMENTAL
Intervention: Intravesical resiniferatoxin (RTX) instillation plus hydrodistention
Number of subjects: 18

Group type: COMPARATOR
Intervention: Hydrodistention only
Number of subjects: 18
Study: 19834467

Group type: EXPERIMENTAL
Intervention: Physical activity (PA) intervention involving moderate intensity aerobic, strength, balance, and flexibility exercise (150 min per week)
Number of subjects: 424

Group type: COMPARATOR
Intervention: Successful aging (SA) intervention involving weekly educational workshops
Number of subjects: 424
Study: 18453642

Group type: EXPERIMENTAL
Intervention: Multimodal intervention (Taiji exercises, cognitive-behavioral therapies, support group)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Attention-control educational programs
Number of subjects: 43
Study: 15824252

Group type: EXPERIMENTAL
Intervention: STN stimulation
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: GPi stimulation
Number of subjects: 23
Study: 12877571

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg (formulation A)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg (formulation B)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg (formulation A)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference formulation 500 mg (formulation C)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference formulation 750 mg (formulation B)
Number of subjects: 24
Study: 10823406

Group type: EXPERIMENTAL
Intervention: d-fenfluramine (dFEN)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 8889283

Group type: EXPERIMENTAL
Intervention: 200 mg moclobemide b.i.d. for 16 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 5 mg selegiline b.i.d. for 16 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combined treatment of moclobemide and selegiline
Number of subjects: 24

Group type: COMPARATOR
Intervention: Moclobemide monotreatment
Number of subjects: 24
Study: 1905394

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG‐fermented milk product, 125 g (10(10‐11) colony‐forming units) twice daily (group 1)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG freeze‐dried powder, one dose (10(10‐11) colony‐forming units) twice daily (group 2)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo, a pasteurized yogurt, 125 g twice daily (group 3)
Number of subjects: 71
Study: 6359379

Group type: EXPERIMENTAL
Intervention: Pneumovax (14-valent pneumococcal vaccine)
Number of subjects: 405

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 405
Study: 30277569

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT+)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Surgery alone (RT-)
Number of subjects: 125
Study: 27548644

Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch-up (ABC)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 24
Study: 24567288

Group type: EXPERIMENTAL
Intervention: Community approaches (e.g., Chinese schools, stores, health fairs, and personal networks)
Number of subjects: 1119

Group type: COMPARATOR
Intervention: Physician letter followed by telephone calls
Number of subjects: 1119
Study: 22831821

Group type: EXPERIMENTAL
Intervention: Request for consent by a member of the research study team
Number of subjects: 1109

Group type: EXPERIMENTAL
Intervention: Age of the child (≥4 years)
Number of subjects: 1109

Group type: EXPERIMENTAL
Intervention: Presence of vesicoureteric reflux
Number of subjects: 1109

Group type: EXPERIMENTAL
Intervention: Inpatient management of the index infection
Number of subjects: 1109

Group type: EXPERIMENTAL
Intervention: Multiple (≥4) symptoms at presentation
Number of subjects: 1109
Study: 20399327

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 17706

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17706
Study: 17952791

Group type: EXPERIMENTAL
Intervention: Dug wells
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Three-pitcher filters
Number of subjects: 640

Group type: COMPARATOR
Intervention: Control
Number of subjects: 640
Study: 16313377

Group type: EXPERIMENTAL
Intervention: Continued support from a stroke nurse
Number of subjects: 176

Group type: COMPARATOR
Intervention: Usual care and follow‐up
Number of subjects: 176
Study: 12423299

Group type: EXPERIMENTAL
Intervention: Single-Incision (SI)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Free Gingival Graft (FGG)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Trap-Door (TD)
Number of subjects: 36
Study: 9695714

Group type: EXPERIMENTAL
Intervention: CYP2C19 in patients with liver disease
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: CYP2D6 in patients with liver disease
Number of subjects: 28

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 28
Study: 8083452

Group type: EXPERIMENTAL
Intervention: nedocromil sodium (4 mg) four times a day for 10 weeks
Number of subjects: 110

Group type: COMPARATOR
Intervention: placebo four times a day for 10 weeks
Number of subjects: 110
Study: 2729661

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 0.6% parachlorometaxylenol
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 0.3% triclosan
Number of subjects: 80

Group type: COMPARATOR
Intervention: Nonantimicrobial control soap
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: All products (6 times/day)
Number of subjects: 80
Study: 47421

Group type: EXPERIMENTAL
Intervention: Polyglycolic-acid subcuticular skin closure
Number of subjects: 152

Group type: COMPARATOR
Intervention: Interrupted silk skin closure
Number of subjects: 152